Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory larg...
Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA
Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )
13 Dec 2021
EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free ...
Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France
EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free survival 3 years after TKIs ( Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France )
13 Dec 2021
Real world data supports ciltacabtagene autoleucel as effective option for tripl...
Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Sp...
Real world data supports ciltacabtagene autoleucel as effective option for triple-class exposed r/r MM ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )
12 Dec 2021
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with...
Dr Martin Kaiser - The Institute of Cancer Research, London UK
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM ( Dr Martin Kaiser - The Institute of Cancer Research, London  UK )
12 Dec 2021
Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted cons...
Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )
12 Dec 2021
Latest in combination therapy for NDMM patients
Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
Latest in combination therapy for NDMM patients ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )
12 Dec 2021
Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neop...
Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA
Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients ( Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA )
11 Dec 2021
Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL
Prof Brian Hill - Cleveland Clinic, Cleveland, USA
Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL ( Prof Brian Hill - Cleveland Clinic, Cleveland, USA )
11 Dec 2021
Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma
Prof Elizabeth Budde - City of Hope, Duarte, USA
Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma ( Prof Elizabeth Budde - City of Hope, Duarte, USA )
11 Dec 2021
Initial treatment options for relapsed/refractory multiple myeloma patients
Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Sp...
Initial treatment options for relapsed/refractory multiple myeloma patients ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )
11 Dec 2021
ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iN...
Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston...
ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iNHL ( Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Dec 2021
Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LB...
Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora, U...
Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LBCL ( Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora, USA )
11 Dec 2021